We fully agree with Costantino and colleagues that differences in baseline characteristics may confound the results of a randomized controlled trial. Therefore, it is important to stress that the detailed description of demographic variables, symptoms, physical examination, vital signs, and laboratory analyses clearly showed that the BNP group and the control group were well matched in the B-Type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) study.1,2 Therefore, it is appropriate to conclude from the BASEL data that BNP testing is cost-effective in patients with acute dyspnea.
Mueller C, Laule-Kilian K, Christ M, Perruchoud AP. Utility of B-Type Natriuretic Peptide Testing in the Emergency Department—Reply. Arch Intern Med. 2006;166(20):2288. doi:10.1001/archinte.166.20.2288-a